Fangzhou Leads AI Healthcare Push in China

Fangzhou Inc. is at the forefront of China's AI healthcare initiative as the country issues a digital transformation roadmap for the pharmaceutical industry, announced in a press release. The 2025-2030 Pharmaceutical Industry Digital Transformation Implementation Plan, issued by seven Chinese regulatory bodies, emphasizes the integration of AI and big data to enhance pharmaceutical development and production.

Fangzhou, a leader in Internet healthcare solutions, is leveraging its "AI + H2H Smart Healthcare Ecosystem" to improve chronic disease management and precision services. The company aims to support China's "AI + Healthcare" blueprint through technological innovation, aligning with national priorities.

The Implementation Plan encourages collaboration between enterprises, hospitals, and research institutes to develop impactful AI applications. Fangzhou's infrastructure, powered by AI, big data, and cloud computing, is transforming healthcare accessibility and patient experiences, showcasing the pivotal role of AI in the industry.